Promotion of lymphocyte growth by high density lipoproteins (HDL). Physiological significance of the HDL binding site.
The characteristics and physiological relevance of the high density lipoprotein (HDL) binding site on unstimulated and mitogen activated human peripheral blood lymphocytes have been investigated. At 37 degrees C, specific binding/uptake of fluorescent (dioctadecylin-docarbocyanine, DiI) HDL was observed by cells from healthy donors as well as by those from low density lipoprotein receptor-defective patients; mitogen activated T-blasts exhibited a markedly elevated DiI-HDL uptake compared to resting T-cells. Binding was saturable at 37 degrees C and of high affinity, with a Kd of 5 x 10(-8) M. It was blocked by anti-apoAI polyclonal antibodies (F(ab)2 fraction), but not by anti-apolipoprotein (apo)E, anti-apoAII, or anti-apoB, and was inhibited competitively by HDL apoproteins and an apoAI-protein A fusion protein. T-cell associated DiI-HDL was increased by trypsin treatment (of the cells) and decreased by activation in the presence of HDL or low density lipoprotein. Comparison of the concentration dependencies of growth promotion and specific cell association of HDL indicated that two mechanisms of lipid exchange may be in operation: one a binding-dependent mechanism of cholesterol exchange, with maximal effect in the HDL concentration range (20-200 micrograms/ml) in which specific binding increases rapidly, and the other a binding-independent exchange of lipids effective at concentrations in which specific binding is saturated (300-5000 micrograms/ml).
Jürgens
G
G
Institute for Medical Biochemistry, University of Graz, Austria.
Xu
Q B
QB
Huber
L A
LA
Böck
G
G
Howanietz
H
H
Wick
G
G
Traill
K N
KN
D000328:Adult; D000945:Antigens, Differentiation, T-Lymphocyte / Q000032:analysis; D001667:Binding, Competitive; D002352:Carrier Proteins; D002478:Cells, Cultured; D005260:Female; D006801:Humans; D007700:Kinetics; D008075:Lipoproteins, HDL / Q000502:physiology*; D008148:Lovastatin / Q000494:pharmacology; D008213:Lymphocyte Activation / Q000187:drug effects; D008214:Lymphocytes / Q000166:cytology / Q000276:immunology*; D008297:Male; D016601:RNA-Binding Proteins; D011956:Receptors, Cell Surface / Q000502:physiology*; D018110:Receptors, Lipoprotein; D014357:Trypsin
D000945:Antigens, Differentiation, T-Lymphocyte; D002352:Carrier Proteins; D008075:Lipoproteins, HDL; D016601:RNA-Binding Proteins; D011956:Receptors, Cell Surface; D018110:Receptors, Lipoprotein; C031616:high density lipoprotein receptors; C075197:high density lipoprotein binding protein; D008148:Lovastatin; D014357:Trypsin